Gilead Sciences (GILD) and its Kite unit have entered into a three-year cancer immunotherapy research collaboration with oNKo-innate. The goal: to discover and …
Gilead Sciences’ (GILD) remdesivir has been grabbing the headlines recently and has positioned itself as a strong candidate for COVID-19. GILD’s share price …
Shares of cancer therapy researcher Arcus Biosciences (RCUS) traded up over 50% in after-hours trading on Wednesday following a Bloomberg report indicating that …
Gilead’s (GILD) remdesivir study in China for mild-moderate Covid-19 patients has just been suspended due to poor enrollment. The news comes as the …
Gilead (GILD) is now working in consultation with regulatory authorities to establish additional expanded access programs for remdesivir, the company’s investigational medicine for …
Almost three months have passed since COVID-19 began its spread beyond China’s borders, and the market remains in free fall. Capping off another volatile week, stocks fell on Friday April 3 in response …
With the number of confirmed COVID-19 cases rising despite worldwide lockdowns and social distancing efforts, the biotech industry is taking action. In just two months since …
The coronavirus’ grip on the market continues. Since the beginning of February, the S&P 500 has shed 8.
Congrats! Gilead Sciences (GILD) has just appointed Daniel O’Day as the Chief Executive Officer of the pharmaceutical giant.
In a landmark advancement against the onslaught of AIDS, the FDA approved today a once-daily single tablet regimen (STR) of Gilead Sciences (NASDAQ:GILD), as a complete …
